Table 1.
Baseline characteristics of 907 participants, EPICOS randomized trial
| Characteristic | TDF/FTC + HCQ (n = 220) |
TDF/FTC (n = 233) | HCQ (n = 231) | Placebo (n = 223) |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 85 (38.6) | 93 (39.9) | 82 (35.5) | 80 (35.9) |
| Female | 135 (61.4) | 140 (60.1) | 149 (64.5) | 143 (64.1) |
| Age (y), median (range) | 38.0 (18.0, 65.0) | 39.0 (18.0, 68.0) | 38.0 (18.0, 65.0) | 38.0 (18.0, 65.0) |
| Occupation, n (%) | ||||
| Physician | 71 (32.3) | 68 (29.2%) | 74 (32.0%) | 66 (29.6%) |
| Nurse | 63 (28.6) | 77 (33.0%) | 67 (29.0%) | 72 (32.3%) |
| Medical student on clinical rotation | 59 (26.8) | 58 (24.9) | 59 (25.5) | 53 (23.8) |
| Other, with direct patient contact | 13 (5.9) | 13 (5.6) | 11 (4.8) | 11 (4.9) |
| Other, without direct patient contact | 13 (5.9) | 10 (4.3) | 15 (6.5) | 18 (8.1) |
| Unknown | 1 (0.5) | 7 (3.0) | 5 (2.2) | 3 (1.3) |
| Comorbidities, n (%) | ||||
| Cardiac disease | 3 (1.4) | 0 | 1 (0.4) | 2 (0.9) |
| Hypertension | 17 (7.7) | 15 (6.4) | 4 (1.7) | 19 (8.5) |
| Pulmonary disease | 0 | 0 | 0 | 0 |
| Asthma | 17 (7.7) | 8 (3.4) | 20 (8.7) | 9 (4.0) |
| Neoplasia | 4 (1.8) | 4 (1.7) | 2 (0.9) | 1 (0.4) |
| Diabetes | 4 (1.8) | 3 (1.3) | 1 (0.4) | 3 (1.3) |
| Autoimmune disease | 5 (2.3) | 7 (3.0) | 4 (1.7) | 2 (0.9) |
| Country, n (%) | ||||
| Spain | 139 (63.2) | 151 (64.8) | 148 (64.1) | 144 (64.6) |
| Venezuela | 31 (14.1) | 31 (13.3) | 32 (13.9) | 29 (13.0) |
| Bolivia | 50 (22.7) | 51 (21.9) | 51 (22.1) | 50 (22.4) |
HCQ, hydroxychloroquine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.